Hand Function Outcome After the Application of Transfer Energy Capacitive and Resistive on Post-b… (NCT07660328) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Hand Function Outcome After the Application of Transfer Energy Capacitive and Resistive on Post-burn Patients Presented With Carpal Tunnel Syndrome
Egypt52 participantsStarted 2026-06-16
Plain-language summary
Carpal Tunnel Syndrome (CTS) is a common entrapment neuropathy that can develop as a secondary complication following deep burns involving the hand or wrist. Post-burn CTS arises due to factors such as fibrosis, edema, and scar contracture, which may increase pressure on the median nerve within the carpal tunnel, leading to significant pain, sensory disturbances, and impaired hand function Recent studies support the effectiveness of Transfer Energy Capacitive and Resistive (TECAR ) therapy in idiopathic CTS, showing improvements in pain, symptom severity, and function, as measured by validated tools such as the Boston Carpal Tunnel Questionnaire (BCTQ) and Visual Analogue Scale (VAS).
A study reported that both TECAR and ultrasound groups showed significant symptom improvement after treatment, although ultrasound had more sustained effects on median nerve cross-sectional area at 3 months
Who can participate
Age range
20 Years – 40 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Participant is between 20 and 40 years of age.
* Diagnosed with mild to moderate carpal tunnel syndrome (CTS).
* History of an upper limb burn, with the percentage of the Total Body Surface Area (TBSA) ranging from 20% to 25%.
* Upper limb burn is diagnosed as a 2nd or 3rd-degree burn complicated with carpal tunnel syndrome.
* Carpal tunnel syndrome diagnosis is clinically confirmed using physical examination, including a positive Tinel's sign and positive Phalen's test.
* Participant provides written informed consent before enrollment.
Exclusion Criteria:
* History of double crush syndrome, cervical radiculopathy, or fibromyalgia.
* History of wrist fracture or distal radius fracture.
* Diagnosis of systemic or local diseases that contribute to peripheral neuropathy, including Diabetes Mellitus or rheumatoid arthritis (RA).
* Diagnosis of hypothyroidism, skin diseases, or peripheral vascular diseases.
* Current or past history of cancer.
* Use of a hand or wrist splint within the past three months.
* Presence of an implanted pacemaker or electrical prosthesis.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Symptom Severity
Timeframe: Baseline and 2 weeks
2
Functional Status
Timeframe: Baseline and 2 weeks.
3
Grip Strength
Timeframe: Baseline and 2 weeks.
Trial details
NCT IDNCT07660328
SponsorCairo University
Sponsor typeOTHER
Study typeINTERVENTIONAL
Primary completion2026-10-30
Contact for this trial
Ahmed abdelnasr Mohamed Youness, Demonstrator (TA)